Observation Of The Efficacy Of Pioglitazone Metformin Tablets In The Treatment Of Polycystic Ovary Syndrome With Insulin Resistance

Objective:By observing clinical efficacy of pioglitazone metformin tablets and metformin in the treatment of polycystic ovary syndrome(PCOS)with insulin resistance(IR),to provide clinical evidence for the treatment of polycystic ovary syndrome with insulin resistance(IR).Methods:From January 2017 to December 2017,a prospective study was conducted on 40 patients with PCOS and IR diagnosed in a gynecology clinic at Yan'an Hospital,Kunming.According to BMI,20 patients were divided into obese group(A group,B group)and 20 non-obese patients(C group,D group).In group A and C,10 patients in each group were control group(MET group)and were given oral metformin.For treatment,10 patients in group B and D were observed in the observation group(combined group).They were treated with oral pioglitazone metformin tablets,and were contacted,followed,and monitored by the WeChat network platform.Determination of luteinizing hormone(LH),follicle stimulating hormone(FSH),testosterone(T),fasting plasma glucose(FPG),fasting insulin(FINS),total cholesterol(TC),triglyceride(TG),high-density lipoprotein(HDL-C),low-density lipoprotein(LDL-C),homeostasis model insulin resistance index(HOMA-IR),body mass index(BMI)and other indicators,after 12 weeks of treatment,the above indicators were measured again to compare the indexes.Change the situation.SPSS 22.0 statistical softwarewas used for statistical analysis.Results:?Age and BMI:There was no significant difference in age between the 4 groups,ranging from 18 to 32 years old,with an average of 24.23±3.75 years old.There was no significant difference in BMI between the obese group(A and B groups)before treatment.The average BMI was 28.17±2.28 kg/m2.There was no significant difference in BMI between the non-obese group(C and D).The average BMI was 20.58±1.80 kg/m2.?Before treatment:FINS,Homa IR,BMI,TG,and LDL-C were significantly higher in the obese group than in the non-obese group(P<0.01),and LH,LH/FSH,and HDL-C were lower in the obese group(P<0.05).T,FPG,FSH,and TC were not statistically different(P>0.05).? After 12 weeks of treatment:BMI,FINS,Homa-IR,T,LH,LH/FSH,FPG,TC,TG,and LDL-C all decreased significantly in group A and group B,and FSH and HDL-C increased in group A(P<0.05).<0.01).In non-obesity group,FINS,Homa-IR,LH,LH/FSH,T,TG,and LDL-C were significantly lower in group C and D,and HDL-C was increased(P<0.05).BMI,FPG,and FSH were not statistically significant.(P>0.05).FINS,Homa-IR,FPG,TC,TG,LDL-C,T in obese group were significantly lower than those in non-obesity group,and HDL-C was increased(P<0.01).Reproductive hormones LH,LH/FSH in non-obesity group were significantly lower than those in obese group(P<0.01).In the metformin group(group A and C)and the pioglitazone metformin tablets group(group B and D),the BMI and TC in group B were significantly lower than those in group A(P<0.01).The FINS and LDL-C in group D were significantly lower than those in group C(P<0.05),the other indicators were not statistically different(P>0.05).ConcIusion:The patients with PCOS and IR have abnormal glucose and lipid metabolism at different levels,and improving insulin resistance and reducing hyperinsulinemia are the key to the treatment of PCOS with IR.Obesity can aggravate insulin resistance and metabolic abnormalities in PCOS patients.The study found that metformin and pioglitazone metformin tablets have improved insulin resistance and lipid metabolism disorders in patients with PCOS and IR,and the improvement of obese patients with PCOS is more obvious.Pioglitazone metformin tablets have better clinical effects than metformin alone in improving IR and glucose and lipid metabolism.In this study,the patients were followed up through the WeChat network platform to optimize the diagnosis and treatment procedures and facilitate communication.This strategy is conducive to the prevention and treatment of PCOS and the education of reproductive health.It is a follow-up research model for the diagnosis and treatment of outpatients with chronic diseases.The next step will be to extend the follow-up period and effectively observe the comprehensive indicators and fertility status of PCOS patients.